PMID- 36251793
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230330
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 32
IP  - 3
DP  - 2023 Mar
TI  - CLIC1 plasma concentration is associated with lymph node metastases in oral 
      squamous cell carcinoma.
PG  - 341-347
LID - 10.17219/acem/154621 [doi]
AB  - BACKGROUND: Previous studies have shown that the chloride intracellular channel 1 
      (CLIC1) protein is overexpressed in oral squamous cell carcinoma (OSCC) and 
      nasopharyngeal carcinoma. Patients with these diseases had significantly higher 
      CLIC1 plasma levels than healthy controls. OBJECTIVES: To determine the plasma 
      concentration of CLIC1 in patients with OSCC and laryngeal squamous cell 
      carcinoma (LSCC). MATERIAL AND METHODS: We collected blood samples from patients 
      diagnosed with OSCC (n = 13) and LSCC (n = 7), as well as from healthy controls 
      (n = 8). The blood samples were centrifuged to obtain plasma and stored at -80 degrees C. 
      The CLIC1 plasma concentration was determined using enzyme-linked immunosorbent 
      assay (ELISA). RESULTS: The mean CLIC1 plasma concentration was higher in the 
      OSCC group than in the LSCC and control groups. Patients with OSCC and nodal 
      metastases had significantly higher CLIC1 plasma concentration levels than 
      nonmetastatic patients (p < 0.0001; Tukey's multiple comparisons test) and 
      controls (p = 0.0004). The CLIC1 concentration correlated significantly with the 
      presence of nodal spread (p = 0.0003; Spearman's r = 0.8613) and overall TNM 
      staging (p = 0.0167; Spearman's r = 0.6620). No differences in CLIC1 plasma 
      levels were observed between the LSCC and control groups. The CLIC1 plasma 
      concentration was not associated with age, sex, tumor stage, or tumor grade. 
      CONCLUSIONS: There were no differences in CLIC1 plasma concentration between 
      healthy controls and patients with LSCC. However, our findings suggest that the 
      presence of this protein in plasma may be associated with lymphatic metastasis in 
      patients with OSCC. More research is needed to confirm this possible association.
FAU - Wojtera, Bartosz Pawel
AU  - Wojtera BP
AD  - Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan 
      University of Medical Sciences, Poland.
FAU - Sobecka, Agnieszka
AU  - Sobecka A
AD  - Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan 
      University of Medical Sciences, Poland.
AD  - Radiobiology Lab, Department of Medical Physics, Greater Poland Cancer Centre, 
      Poznan, Poland.
FAU - Szewczyk, Mateusz
AU  - Szewczyk M
AD  - Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan 
      University of Medical Sciences, Poland.
FAU - Machczynski, Piotr
AU  - Machczynski P
AD  - Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan 
      University of Medical Sciences, Poland.
FAU - Suchorska, Wiktoria Maria
AU  - Suchorska WM
AD  - Radiobiology Lab, Department of Medical Physics, Greater Poland Cancer Centre, 
      Poznan, Poland.
AD  - Department of Electroradiology, Poznan University of Medical Sciences, Poland.
FAU - Golusinski, Wojciech
AU  - Golusinski W
AD  - Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan 
      University of Medical Sciences, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CLIC1 protein, human)
RN  - 0 (Chloride Channels)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Lymphatic Metastasis
MH  - *Mouth Neoplasms/pathology
MH  - *Head and Neck Neoplasms
MH  - Biomarkers, Tumor/analysis
MH  - Chloride Channels
OTO - NOTNLM
OT  - CLIC1
OT  - HNSCC
OT  - OSCC
OT  - cancer plasma marker
OT  - oral squamous cell carcinoma
EDAT- 2022/10/18 06:00
MHDA- 2023/03/30 06:11
CRDT- 2022/10/17 14:12
PHST- 2023/03/30 06:11 [medline]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/17 14:12 [entrez]
AID - 10.17219/acem/154621 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2023 Mar;32(3):341-347. doi: 10.17219/acem/154621.